Equity Insights Mar. 22nd: EMC, Westport Innovations, Watson Pharmaceuticals, Microsoft, Alkermes

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Microsoft Corporation (NASDAQ:MSFT): Morgan Stanley said Windows 8 is somewhat discounted in Microsoft shares but Office 15 is not reflected and will be the next catalysts for shares. The firm rates Microsoft an Overweight.

EMC Corporation (NYSE:EMC): Credit Suisse raised EMC’s Information Storage segment estimates and said the company remains a preferred IT hardware pick. Shares are Outperform rated.

Westport Innovations Inc. (NASDAQ:WPRT): After Westport’s (NASDAQ:WPRT) stock declined following Cummins’ (NYSE:CMI) announcement that it will develop a 15 Liter engine for the heavy-duty truck market, JMP Securities believes that Westport’s 15 liter engine will be dominant for heavy duty applications. The firm increased its target on Westport to $54 from $48 while reiterating an Outperform rating.

Watson Pharmaceuticals Inc. (NYSE:WPI): After media outlets reported that Watson is nearing a deal to buy generic drug maker Actavis, RBC Capital thinks that such a deal would likely be highly accretive while effectively diversifying Watson’s revenues. The firm believes that Watson’s shares could advance following the company’s acquisition of Actavis, and RBC recommends buying Watson shares.

Alkermes, Inc. (NASDAQ:ALKS): Jefferies says now is the time to consider building or adding to positions of Alkermes with the overhang of Elan’s share sale now behind the company. Jefferies sees many reasons to like the Alkermes story and reiterates a Buy rating on the stock with a $24 price target.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:
Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business